Lemaitre Vascular (LMAT) Tops Q2 EPS by 4c, Beats on Revenue; Offers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
LeMaitre Q2 2023 Financial Results
August 1, 2023 4:05 PM EDTBURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq: LMAT), a provider of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance.
Q2 2023 Financial Results
Sales $50.1mm, +19% (+16% organic) vs. Q2 2022Op. income $9.5mm, +63% (+8% adjusted)Op. margin 19%Net income $8.1mm, +130% (+27% adjusted)Earnings per diluted share $0.36, +127% (+25% adjusted)Cash up $9.2mm to $90.2mmBovine patches (+16%),... More
